Neurogenic orthostatic hypotension is a rare, chronic and often debilitating drop in blood pressure upon standing that is associated with Parkinson's disease, multiple-system atrophy and pure autonomic failure.
Symptoms of NOH include dizziness, lightheadedness, blurred vision, fatigue and fainting when a person stands.
"People with neurogenic orthostatic hypotension are often severely limited in their ability to perform routine daily activities that require walking or standing," Dr. Norman Stockbridge, director of the Division of Cardiovascular and Renal Drugs in the FDA's Center for Drug Evaluation and Research, said in a statement.
"There are limited treatment options for people with NOH and we are committed to helping make safe and effective treatments available."
The FDA is approving Northera under the accelerated approval program, which allows for approval of a drug to treat a serious disease based on clinical data showing that the drug has an effect on an intermediate clinical measure -- in this case, short-term relief of dizziness -- that is reasonably likely to predict the outcome of ultimate interest.
This program provides patient access to promising drugs while the company conducts post-approval clinical trials to verify the drug's clinical benefit, which for this approval is a long-term effect on patient symptoms in NOH, a chronic disease.
Northera, produced by Chelsea Therapeutics Inc., has a boxed warning to alert healthcare professionals and patients about the risk of increased blood pressure while lying down, or supine hypertension, a common problem that affects people with primary autonomic failure and can cause stroke.
It is essential that patients be reminded that they must sleep with their head and upper body elevated, the FDA said. Supine blood pressure should be monitored prior to and during treatment and more frequently when increasing doses.
The effectiveness of Northera was shown through two weeks in two clinical trials in people with NOH. People taking Northera reported a decrease in dizziness, lightheadedness, feeling faint, or feeling as if they might black out compared to those taking a placebo. Durability of the improvement in patient symptoms beyond two weeks has not been demonstrated, officials said.
Swim Week Miami Beach 2014 [PHOTOS]